entertainment -WSS

entertainment

author：entertainment 2025-09-30 01:13:19 - browse：4

The headquarter of Biotechnology company Ionis Pharmaceuticals, consists of glass windows, pale yellow exteriors and plants outside the building — biotech coverage from STAT — courtesy Ionis Pharmaceuticals

Ionis Pharmaceuticals, a California company that pioneered a whole class of RNA-targeted medicines, reported on Friday that a pair of late-stage trials showed that its experimental therapy for hereditary angioedema benefitted patients — including those taking drugs currently on the market.

In one of the Phase 3 trials, dubbed OASIS, patients with hereditary angioedema, a rare disease characterized by severe bouts of swelling, were given injections of donidalorsen either monthly or every two months. Those in the former group had an 81% lower monthly rate of swelling attacks after 25 weeks than patients given a placebo, while the reduction compared to placebo was 55% for those treated every two months.

The other study, OASISplus, found that donidalorsen’s benefits deepened and converged after up to an additional year of treatment, with swelling attack rates dropping by 92% to 93% regardless of how often patients were dosed. Notably, this study also tracked patients who switched over to donidalorsen from existing therapies meant to prevent swelling attacks, including drugs sold by Takeda and BioCryst Pharmaceuticals. Patients who switched to the Ionis drug saw their swelling attack rates drop by 62% compared to previous treatment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： A Q&A with Aletha Maybank, AMA’s chief health equity officer

hotspot

WSS

How to address the problem of discarded donor organs

Bird flu researchers hone in on Finland’s mink farms

An inside look at PIPEs, biotech's buzzy new financing tool

Novo Nordisk touts Wegovy study, but still struggling with supply

Indictment alleges Trump's ex

Senators push IRS to launch nonprofit hospital probe

leisure time

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

Guidelines to prevent youth baseball injuries need more muscle

House looks to weaken Medicare negotiation

As demand for Covid shots wanes, Moderna seeks its next success

Health AI: on the border between health care and tech

23andMe had bad news about my health. I wish a person had delivered it

Biden administration begins canceling student loan debt for 804,000 borrowers

23andMe had bad news about my health. I wish a person had delivered it

In search for therapies for solid tumors, companies turn to claudin

How to save PrEP access — and even expand it

RaDonda Vaught to speak at CommonSpirit event on patient safety

focus

Timeline: How the deadly wildfires took over Maui day by day

Hospitals are dialing back on venture capital investing

Readout LOUD Podcast: Legal insider trading, booming biotech stocks

AstraZeneca loses challenge to Medicare drug price negotiation

FDA does about

Bird flu researchers hone in on Finland’s mink farms

leisure time

knowledge

hotspot

hotspot